Regulation of angiotensin II type 1 receptor expression in ovarian cancer: A potential role for BRCA1

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Bi, Fang Fang ^a   Li, Da ^a   Cao, Chen ^b   Li, Chun Yan ^c   Yang, Qing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Angiotensin II type 1 receptor; BRCA1; Ovarian cancer

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BRCA1 PROTEIN; GENOMIC DNA; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EID: 84889781103     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-89     Document Type: Article

References (31)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Pruthi S, Gostout BS, Lindor NM, Mayo Clin Proc 2010 85 1111 1120 10.4065/mcp.2010.0414 21123638
3. IGF-1 and BRCA1 signalling pathways in familial cancer. Werner H, Bruchim I, Lancet Oncol 2012 13 537 e544 10.1016/S1470-2045(12)70362-5 23182194
4. Renin-angiotensin system: upgrade of recent knowledge and perspectives. Herichova I, Szantoova K, Endocr Regul 2013 47 39 52 10.4149/endo-2013-01-39 23363256
5. Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Piastowska-Ciesielska AW, Płuciennik E, Wójcik-Krowiranda K, Bieńkiewicz A, Bednarek A, Ochȩdalski T, Tumour Biol 2012 33 767 774 10.1007/s13277-011-0292-0 22170435
6. Correlation between VEGFR-2 receptor kinase domain-containing receptor (KDR) mRNA and angiotensin II receptor type 1 (AT1-R) mRNA in endometrial cancer. Piastowska-Ciesielska AW, Płuciennik E, Wójcik-Krowiranda K, Bieńkiewicz A, Nowakowska M, Pospiech K, Bednarek AK, Domińska K, Ochȩdalski T, Cytokine 2013 61 639 644 23273598
7. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Kikkawa F, Mizuno M, Shibata K, Kajiyama H, Morita T, Ino K, Nomura S, Mizutani S, Am J Obstet Gynecol 2004 190 1258 1263 10.1016/j.ajog.2003.12.013 15167827 (Pubitemid 38692206)
8. Physiopathology of the renin-angiotensin system in the ovary. De Nuccio I, Salvati G, Genovesi G, Paolini P, Marcellini L, Schiavello V, Re M, Minerva Endocrinol 1999 24 77 81 10941427
9. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, Nomura S, Kikkawa F, Br J Cancer 2006 94 552 560 10.1038/sj.bjc.6602961 16434990 (Pubitemid 43289760)
10. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F, Clin Cancer Res 2005 11 2686 2694 10.1158/1078-0432.CCR-04-1946 15814650 (Pubitemid 40569470)
11. Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis. Song L, Zhang SL, Bai KH, Yang J, Xiong HY, Li X, Liu T, Liu HR, J Ovarian Res 2013 6 22 10.1186/1757-2215-6-22 23561060
12. Effect of AT1R knockdown on ishikawa cell proliferation induced by estrogen. Yang Q, Su Q, Wang G, Bi F, Sa R, Arch Gynecol Obstet 2012 286 481 487 10.1007/s00404-012-2305-7 22484478
13. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, Sun L, Sui G, Cai L, Dong X, Cancer Lett 2013 328 318 324 10.1016/j.canlet.2012.10. 006 23092556
14. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM, Cancer Res 2009 69 1273 1278 10.1158/0008-5472.CAN-08-2954 19190334
15. Promoter hypomethylation, especially around the E26 transformation- specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. Bi FF, Li D, Yang Q, BMC Cancer 2013 13 90 10.1186/1471-2407-13-90 23442605
16. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Bélanger C, Dion F, Liu Q, Skolnick M, Goldgar D, Shattuck-Eidens D, Labrie F, Narod SA, Nat Genet 1994 8 392 398 10.1038/ng1294-392 7894492 (Pubitemid 24375607)
17. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, Balkwill FR, Mol Cancer Ther 2006 5 382 390 10.1158/1535-7163.MCT-05-0303 16505113
18. Epigenetic reprogramming in cancer. Suvà ML, Riggi N, Bernstein BE, Science 2013 339 1567 1570 10.1126/science.1230184 23539597
19. BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Ma Y, Fan S, Hu C, Meng Q, Fuqua SA, Pestell RG, Tomita YA, Rosen EM, Mol Endocrinol 2010 24 76 90 10.1210/me.2009-0218 19887647
20. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM, Mol Endocrinol 2007 21 1905 1923 10.1210/me.2006-0397 17505062 (Pubitemid 47173800)
21. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaelian I, Mazoyer S, EMBO Mol Med 2011 3 279 290 10.1002/emmm.201100136 21472990
22. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S, Int J Cancer 2009 125 2820 2828 10.1002/ijc.24684 19551867
23. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Srinivas G, Annab LA, Gopinath G, Banerji A, Srinivas P, Mol Carcinog 2004 39 15 25 10.1002/mc.10164 14694444 (Pubitemid 38056193)
24. BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site. Kang HJ, Yi YW, Kim HJ, Hong YB, Seong YS, Bae I, Cell Death Dis 2012 3 336 10.1038/cddis.2012.78 22739988
25. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Wen J, Li R, Lu Y, Shupnik MA, Oncogene 2009 28 575 586 10.1038/onc.2008.405 18997820
26. Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM, Mol Endocrinol 2009 23 1135 1146 10.1210/me.2008-0347 19389812
27. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Arrieta O, Pineda-Olvera B, Guevara-Salazar P, Hernández-Pedro N, Morales-Espinosa D, Cerón-Lizarraga TL, la Rosa CH G-D, Rembao D, Segura-Pacheco B, Sotelo J, Br J Cancer 2008 99 160 166 10.1038/sj.bjc.6604431 18594540 (Pubitemid 351920229)
28. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Redondo-Müller MA, Stevanovic-Walker M, Barker S, Puddefoot JR, Vinson GP, Endocr Relat Cancer 2008 15 277 288 10.1677/ERC-07-0068 18310294 (Pubitemid 351449746)
29. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK, Kathleen Cuningham foundation consortium for research into familial breast cancer (kConFab), Nat Med 2011 17 1275 1282 10.1038/nm.2459 21946536
30. BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control. Stefansson OA, Esteller M, Breast Cancer Res 2012 14 304 22423979
31. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Chang S, Sharan SK, Oncotarget 2012 3 5 6 22403740